Related Experiment Videos
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung
R E Favoni1, F Ravera, P Pirani
1Department of Experimental Pharmacology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Abstract:
Human non-small cell lung cancer (N-SCLC), a common malignancy generally unmanageable by conventional cytotoxic chemotherapy, represents a major world health burden. Suramin, a polyanionic drug which appears to interfere with growth-factor/receptor interaction, has recently been shown to be cytostatic for small cell lung cancer cells; it may also be effective for N-SCLC. As insulin-like growth factor I (IGF-I) is a known progression agent for N-SCLC, we have examined the effects of suramin on the 'IGF-I system' in a panel of human N-SCLC cell lines. Colorimetric and thymidine incorporation assays were used to assess cell chemosensitivity whereas a radio-receptor assay was employed to evaluate IGF-I/receptor binding. Suramin reversibly reduced, in a concentration- and time-dependent manner, the growth of each N-SCLC cell line examined either cultured in serum-containing or serum-free medium. Furthermore, suramin caused a concentration-related inhibition of labeled IGF-I peptide specific binding on all cell lines studied. Suramin caused a significant reduction in the Bmax values with only weak variations in the affinity constants (Kd). We hypothesize that suramin interference with IGF-I mitogenic activity is a pathway by which this drug produces its effect in vitro. These data indicate further studies on the mechanism of action and pharmacology of suramin in vivo are warranted.
Insights
Suramin effectively inhibits non-small cell lung cancer (N-SCLC) growth by interfering with insulin-like growth factor I (IGF-I) signaling. This drug warrants further investigation for N-SCLC treatment due to its demonstrated in vitro efficacy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Non-small cell lung cancer (N-SCLC) poses a significant global health challenge, often resistant to traditional chemotherapy.
- Insulin-like growth factor I (IGF-I) is implicated in N-SCLC progression.
- Suramin, a drug interfering with growth factor signaling, has shown potential in cancer treatment.
Purpose of the Study:
- To investigate the effects of suramin on the IGF-I system in human N-SCLC cell lines.
- To determine if suramin exhibits anti-cancer activity against N-SCLC.
- To elucidate the mechanism by which suramin impacts N-SCLC growth.
Main Methods:
- Utilized colorimetric and thymidine incorporation assays to assess cell chemosensitivity.
- Employed radio-receptor assays to evaluate IGF-I/receptor binding.
- Examined suramin's effects on N-SCLC cell lines in both serum-containing and serum-free media.
Main Results:
- Suramin demonstrated reversible, dose- and time-dependent inhibition of N-SCLC cell growth.
- Suramin significantly reduced specific binding of labeled IGF-I to its receptor on N-SCLC cells.
- Suramin decreased Bmax values, indicating reduced receptor availability, with minimal impact on binding affinity (Kd).
Conclusions:
- Suramin's interference with IGF-I mitogenic activity is a likely mechanism for its observed anti-cancer effects in N-SCLC.
- These findings support further in vivo studies on suramin's mechanism of action and pharmacology for N-SCLC treatment.